Literature DB >> 17289865

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.

Mark J Ratain, Theodore G Karrison.   

Abstract

Mesh：

Year:  2007        PMID： 17289865     DOI： 10.1158/1078-0432.CCR-06-2533

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

1.  Resampling phase III data to assess phase II trial designs and endpoints.

Authors:  Manish R Sharma; Theodore G Karrison; Yuyan Jin; Robert R Bies; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

2.  Recommended changes to oncology clinical trial design: revolution or evolution?

Authors:  Mark J Ratain; Rachel W Humphrey; Gary B Gordon; Gwen Fyfe; Peter C Adamson; Thomas R Fleming; Walter M Stadler; Donald A Berry; Carl C Peck
Journal:  Eur J Cancer       Date:  2007-11-05       Impact factor: 9.162

Review 3.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

4.  Clinical trials in the era of personalized oncology.

Authors:  Michael L Maitland; Richard L Schilsky
Journal:  CA Cancer J Clin       Date:  2011-10-27       Impact factor: 508.702

5.  Current issues in oncology drug development, with a focus on Phase II trials.

Authors:  Daniel J Sargent; Jeremy M G Taylor
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

Review 6.  Targeting targeted agents: open issues for clinical trial design.

Authors:  Emilio Bria; Massimo Di Maio; Paolo Carlini; Federica Cuppone; Diana Giannarelli; Francesco Cognetti; Michele Milella
Journal:  J Exp Clin Cancer Res       Date:  2009-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.